An interventional study of Estradiol Valerate and Placebo in Emotion Regulation and Estradiol, sponsored by International Research Training Group 2804. Completed at 1 site in Germany. Open to female participants aged 19 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-15.
Sponsored by International Research Training Group 2804 · Not applicable, Interventional, and Other
Ovarian hormones are not only modulators of cognitive function, emotion regulation and mental health, but also seem to affect brain plasticity and functional connectivity, During the menstrual cycle, women experience cyclic fluctuation of the ovarian hormone estradiol, which is closely associated with neuroplasticity/changes in brain structure in regions with high estradiol receptor density, such as the amygdala, hippocampus/parahippocampus, anterior cingulate cortex (ACC), striatum, and prefrontal cortex (PFC). Further functional connectivity between these areas seems to be associated with hormonal changes dependent on the menstrual cycle phase. But next to estradiol, also other hormones like progesterone fluctuate across the menstrual cycle. In the past, effects of ovarian hormone levels were often investigated in combination. However, one way to disentangle the impact of estradiol from that of other hormones on neuroplasticity, emotion regulation and mood states, can be the experimental increase of estradiol via estradiol administration. In this double-blinded within-subject study, women were administered either estradiol valerate or placebo during the early follicular phase (thus when ovarian hormone concentrations are low) before undergoing neuroimaging.
Parts of the study are already described in Rehbein et al., 2021 and 2022.
In this project the investigators wanted to assess women with/without experimentally elevated estradiol (E2) levels in order to understand E2's effect on volume and resting state functional connectivity. Thus, women underwent fMRI (functional magnetic resonance imaging) scanning twice (with/without elevated E2) to deduce underlying neuronal activation. All participants underwent a structured assessment including demographical data, psychological/clinical data, e.g., structured clinical interview, anxiety traits, depression, emotion regulation traits, self-esteem as well as cognitive abilities, e.g., verbal intelligence, cognitive flexibility) and two (f)MRI measurements (T1/T2, separated by at least 2-3 months), including resting-state and anatomical scans as well as a behavioural emotion regulation task. At T1/T2 either E2 valerate or placebo was administered in a double-blinded, counterbalanced, randomized order.
E2 valerate administration: To experimentally elevate E2 concentrations each woman has received 6mg on two consecutive days (total 12mg) of E2 valerate (Progynova21©) Administration of E2 has been randomly distributed, so that women either received placebo (i.e. leading to an early follicular phase with low ovarian hormone levels) or E2 (i.e. leading to an early follicular phase with high E2 levels) first. Functional resting-state and anatomical data, emotion regulation performance, state anxiety, mood and depression scores have been acquired after the second pill intake. During the emotion regulation task women were asked to either (a) passively view aversive pictures or (b) down regulate their emotional response by e.g. changing their perspective on the picture and then rate their emotional state.
To assess changes in hormone concentrations (E2, progesterone, testosterone) blood samples were obtained before the first and after the second pill intake.
International Research Training Group 2804 is the lead sponsor of 8 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
contraindication for MRI
naturally cycling women during early follicular phase starting with placebo (order was randomly selected)
Drug: Estradiol Valerate · Drug: Placebo
naturally cycling women during early follicular phase starting with estradiol (order was randomly selected)
Drug: Estradiol Valerate · Drug: Placebo
To elevate estradiol levels each woman has received 6mg on two consecutive days (total 12mg) of estradiol valerate (Progynova21©)
Also known as: Progynova21
Placebo (blue-colored hard gelatine capsules completely filled with a mixture of 99.5% mannitol and 0.5% Aerosil (fumed silica)) has been administered (placebo-controlled condition)
Impact of E2 concentration on brain structure
Brain structure (assessed via anatomical MRI scans, MPRAGE) will be compared between E2 and placebo conditions in regions of interest (ROI) (including amygdala, hippocampus/parahippocampus, ACC, striatum, and PFC).
Time frame: From first measurement up to 6 months, with at least two months apart; each time: approx. 6 minutes during neuroimaging
Impact of E2 concentration and state emotion regulation on brain structure
Brain structure (assessed via anatomical MRI scans, MPRAGE, in cm³) will be compared between E2 and placebo conditions in dependence of state emotion regulation ratings in ROIs (as above). State emotion regulation ratings obtained via the emotion regulation task (subjective rating ranging from -200 to 200).
Time frame: From first measurement up to 6 months, with at least two months apart; each time: approx. 6 minutes during neuroimaging (structure) and 20 minutes (emotion regulation task)
Impact of E2 concentration and emotion regulation traits on brain structure
Brain structure (assessed via anatomical MRI scans) will be compared between E2 and placebo conditions in dependence of emotion regulation traits in ROIs (as above). Emotion regulation traits assessed via the Heidelberg Form of Emotion Regulation (HFERST, ranging from 1 to 5) and the Emotion Regulation Questionnaire (ERQ, likert scale 1-7).
Time frame: From first measurement up to 6 months, with at least two months apart; each time: approx. 6 minutes during neuroimaging
Impact of E2 concentration on resting state functional connectivity
Resting state functional connectivity (assessed via resting state fMRI) will be compared between E2 and placebo condition in the whole brain and ROIs (as above).
Time frame: From first measurement up to 6 months, with at least two months apart; each time: approx. 7 minutes during neuroimaging
Impact of E2 concentration and state emotion regulation on connectivity
Resting state functional connectivity (assessed via resting state fMRI) will be compared between E2 and placebo conditions in dependence of emotion regulation ratings in ROIs (as above). State emotion regulation ratings obtained via the emotion regulation task (subjective rating ranging from -200 to 200).
Time frame: From first measurement up to 6 months, with at least two months apart; each time: approx. 7 minutes (connectivity) and 20 minutes (emotion regulation task)
Impact of E2 concentration and emotion regulation traits on functional connectivity
Resting state functional connectivity (assessed via resting state fMRI) will be compared between E2 and placebo conditions in dependence of emotion regulation traits in ROIs (as above). Emotion regulation traits assessed via the Heidelberg Form of Emotion Regulation (HFERST, ranging from 1 to 5) and the Emotion Regulation Questionnaire (ERQ, likert scale 1-7).
Time frame: From first measurement up to 6 months, with at least two months apart; each time: approx. 7 minutes (connectivity) during neuroimaging
Impact of E2 concentration and associated structural brain changes on connectivity
In order to investigate to which degree structural changes in association with E2 concentrations are related to changes in connectivity, both structure and connectivity were assessed via anatomical (MPRAGE) and resting state MRI scans.
Time frame: From first measurement up to 6 months, with at least two months apart; each time before and after pill intake (6 minutes structure and 7 minutes connectivity)
Impact of E2 concentration and self-esteem on brain structure
Brain structure (assessed via anatomical MRI scans, MPRAGE) will be compared between E2 and placebo condition on dependence of self-esteem ratings in ROIs (as above). Self-esteem self-ratings assessed via the Rosenberg Self-Esteem Questionnaire (RSQ).
Time frame: From first measurement up to 6 months, with at least two months apart; each time: approx. 6 minutes during neuroimaging
Impact of E2 concentration and self-esteem on functional connectivity
Resting state functional connectivity (assessed via resting state fMRI) will be compared between E2 and placebo condition on dependence of self-esteem ratings in ROIs (as above). Self-esteem self-ratings assessed via the Rosenberg Self-Esteem Questionnaire (RSQ).
Time frame: From first measurement up to 6 months, with at least two months apart; each time: approx. 7 minutes during neuroimaging
Impact of E2 concentration and subjective mood on brain structure
Brain Structure (assessed via anatomical MRI scans, MPRAGE) will be compared between E2 and placebo condition in dependence of subjective mood in ROIs (as above). Ratings of subjective mood/affect obtained on the neuroimaging day.
Time frame: From first measurement up to 6 months, with at least two months apart; each time: approx. 6 minutes during neuroimaging
Impact of E2 concentration and state anxiety on brain structure
Brain Structure (assessed via anatomical MRI scans, MPRAGE) will be compared between E2 and placebo condition in dependence of state anxiety in ROIs (as above). Ratings of state anxiety (State Anxiety Inventory) obtained on the neuroimaging day
Time frame: From first measurement up to 6 months, with at least two months apart; each time: approx. 6 minutes during neuroimaging
Impact of E2 concentration and subjective mood on functional connectivity
Resting state functional connectivity (assessed via resting state MRI) will be compared between E2 and placebo condition in dependence of subjective mood in ROIs (as above). Ratings of subjective mood/affect obtained on the neuroimaging day.
Time frame: From first measurement up to 6 months, with at least two months apart; each time: approx. 7 minutes during neuroimaging
Impact of E2 concentration and state anxiety on functional connectivity
Resting state functional connectivity (assessed via resting state MRI) will be compared between E2 and placebo condition in dependence of state anxiety in ROIs (as above). Ratings of state anxiety (State Anxiety Inventory) obtained on the neuroimaging day.
Time frame: From first measurement up to 6 months, with at least two months apart; each time: approx. 7 minutes during neuroimaging
Impact of E2 administration on E2 concentrations
Changes in E2 concentrations(pmol/L), will be assessed from blood samples before and after pill intake.
Time frame: From first measurement up to 6 months, with at least two months apart; each time before and after pill intake
Impact of E2 administration on E2-progesterone ratio
Changes in E2-progesterone ratio will be assessed from blood samples before and after pill intake.
Time frame: From first measurement up to 6 months, with at least two months apart; each time before and after pill intake
Impact of E2 administration on testosterone and progesterone concentration
Changes in testosterone and progesterone concentrations (nmol/L) will be assessed from blood samples before and after pill intake.
Time frame: From first measurement up to 6 months, with at least two months apart; each time before and after pill intake
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
International Research Training Group 2804